Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jun 7;13(3):R62.
doi: 10.1186/bcr2899.

Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes

Affiliations

Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes

Michael L Gatza et al. Breast Cancer Res. .

Abstract

Introduction: Breast cancer heterogeneity occurs as a consequence of the dysregulation of numerous oncogenic pathways as well as many non-genetic factors, including tumor microenvironmental stresses such as hypoxia, lactic acidosis, and glucose deprivation. Although the importance of these non-genetic factors is well recognized, it is not clear how to integrate these factors within the genetic framework of cancer as the next logical step in understanding tumor heterogeneity.

Methods: We report here the development of a series of gene expression signatures to measure the influences of microenvironmental stresses. The pathway activities of hypoxia, lactic acidosis, acidosis and glucose deprivation were investigated in a collection of 1,143 breast tumors, which have been separated into 17 breast tumor subgroups defined by their distinct patterns of oncogenic pathways. A validation dataset comprised of 547 breast tumors was also used to confirm the major findings, and representative breast cancer cell lines were utilized to validate in silico results and mechanistic studies.

Results: Through the integrative pathway analysis of microenvironmental stresses and oncogenic events in breast tumors, we identified many known and novel correlations between these two sources of tumor heterogeneity. Focusing on differences between two human epidermal growth factor receptor 2 (HER2)-related subgroups, previously identified based on patterns of oncogenic pathway activity, we determined that these subgroups differ with regards to tumor microenvironmental signatures, including hypoxia. We further demonstrate that each of these subgroups have features consistent with basal and luminal breast tumors including patterns of oncogenic signaling pathways, expression of subtype specific genes, and cellular mechanisms that regulate the hypoxia response. Importantly, we also demonstrate that the correlated pattern of hypoxia-related gene expression and basal-associated gene expression are consistent across HER2-related tumors whether we analyze the tumors as a function of our pathway-based classification scheme, using the intrinsic gene list (ERBB2+), or based on HER2 IHC status. Our results demonstrate a cell lineage-specific phenomenon in which basal-like tumors, HER2-related tumors with high hypoxia, as well as normal basal epithelial cells express increased mRNA levels of HIF-1α compared to luminal types and silencing of HIF-1α results in decreased expression of hypoxia-induced genes.

Conclusions: This study demonstrates differences in microenvironmental conditions in HER2-related subgroups defined by distinct oncogenic pathway activities, and provides a mechanistic explanation for differences in the observed hypoxia response between these subgroups. Collectively, these data demonstrate the potential of a pathway-based classification strategy as a framework to integrate genetic and non-genetic factors to investigate the basis of tumor heterogeneity.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patterns of oncogene, tumor suppressor and microenvironment pathway activity in human breast cancer. (A) Heatmap depicting the two-way hierarchical clustering of patterns of indicated microenvironment stresses (labeled in red) together with oncogenic pathway activities (labeled in black) in a collection of 1,143 human breast tumors. Red and blue indicates a high and low probability of pathway activity, respectively. (B) Pearson Correlation Coefficient (r) values between the activities of the 22 indicated pathways.
Figure 2
Figure 2
HER2 related subgroup 7 is characterized by increased pathway activities of hypoxia and other stresses. (A) Heatmap identifying patterns of oncogenic and micro-environmental pathways activity in the HER2 related tumor subgroups 7 (n = 53) and 10 (n = 59) in the primary dataset of 1,143 tumors; red indicates high predicted pathway activity, blue, low pathway activity. (B) Quantitative assessment of predicted probabilities of microenvironmental conditions in primary dataset demonstrating significantly higher hypoxia (P <0.0001), glucose deprivation (P <0.0001), and acidosis (P <0.0001) but no difference in lactic acidosis levels (P = 0.5140). (C) Heatmap identifying patterns of oncogenic and micro-environmental pathways activity in the HER2 related tumor subgroups 7 (n = 37) and 10 (n = 47) in the validation dataset of 547 tumors; red indicates high predicted pathway activity, blue, low pathway activity. (D) Quantitative assessment of predicted probabilities of microenvironmental conditions in primary dataset demonstrating significantly higher hypoxia (P = 0.0149), glucose deprivation (P <0.0001), and acidosis (P = 0.0008) but no difference in lactic acidosis levels (P = 0.0697).
Figure 3
Figure 3
Subgroup 7 tumors are characterized by increased levels of hypoxia-related gene expression. Subgroup 7 tumors express higher levels of hypoxia-induced genes as compared to subgroup 10 tumors in the (A) primary and the (B) validation datasets. Subgroup 7 tumors express significantly higher levels of HIF-1α mRNA in the (C) primary dataset (P <0.0001) and (D) the validation dataset (P = 0.0016) when compared to subgroup 10 tumors as examined by microarray analysis. (E) Subgroup 7 representative cell line AU565 (P <0.0001) demonstrated higher levels of HIF-1α expression as compared subgroup 10 cell line, HCC202 when examined by RT-PCR under normal (21% O2) and hypoxic (1% O2) conditions. Similarly, significantly higher expression of EPAS1 (HIF-2α) was noted in the subgroup 7 in (F) the primary dataset (P <0.0001) and (G) the validation dataset (P <0.0001) when compared to subgroup 10 tumors by microarray analysis. AU565 (P <0.0001) demonstrated higher levels of EPAS1 (HIF2α) expression as compared subgroup 10 cell line, HCC202, when examined by RT-PCR under normal (21% O2) and hypoxic (1% O2) conditions.
Figure 4
Figure 4
HER2 related tumor subtypes are characterized by basal and luminal features. (A) Heatmap showing the expression level of basal-type specific genes in subgroups 7 and 10 tumors. (B) Subgroup 10 tumors show significantly higher GATA3 mRNA expression (P = 0.0008) as compared to subgroup 7 tumors. (C) Subgroup 10 cell lines (HCC202) demonstrate higher levels of GATA3 expression than subgroup7 cell lines (AU565). (D) Validation of the luminal-basal signatures demonstrates an accurate prediction of basal (mean predicted probability: 0.933) and luminal (mean predicted probability: 0.321) breast tumors (P <0.0001). (E) Validation of luminal-basal signature in validation dataset shown accurate prediction of basal (mean predicted probability: 0.992) and luminal (mean predicted probability: 0.438) tumor status. (F) HER2 related tumors from the primary dataset of 1,143 samples in subgroup 7 demonstrate basal-like features while subgroup 10 tumors are associated with luminal-like features (P <0.0001). (G) HER2 related tumors in the validation dataset show significant enrichment of basal and luminal features in subgroups 7 and 10, respectively (P <0.0001). (H) Validation of subgroup 7/10 signature to predict subgroup7 and 10 characteristics of tumors assigned to subgroup 7 (mean predicted probability: 0.7950) and subgroup 10 (mean predicted probability: 0.2022) with a congruency rate of 84.5% (P <0.0001). (I) Classification of basal and luminal breast cancer cell lines demonstrates a congruency of 72% with basal and luminal status (P <0.0001).
Figure 5
Figure 5
HER2 related tumors demonstrate a significant correlative relationship between basal-like and hypoxia-related gene expression. A positive correlation between basal-like and hypoxia-related gene expression was observed in the tumors assigned to subgroups 7 (highlighted in red) and 10 (highlighted in blue) in the (A) primary (n = 112, P <0.0001) and (F) validation (n = 84, P <0.0001) datasets; in tumors classified as ERBB2+ by the intrinsic gene list in the (B) primary (n = 115, P <0.0001) and (G) validation (n = 54, P = 0.0012) datasets; and in tumors that are HER2+ by IHC in the (C) primary (n = 49, P <0.0001) and (H) validation (n = 33, P = 0.0069) datasets. HIF-1α mRNA expression in IHC HER2+ tumors correlates with hypoxia-related gene expression in the (D) primary (n = 49, P = 0.0256) and (I) validation (n = 33, P = 0.0032) datasets. EPAS1 (HIF-2α) mRNA expression in IHC HER2+ tumors correlates with hypoxia-related gene expression in the (E) primary (n = 49, P = 0.0038) and (J) validation (n = 33, P = 0.0094) datasets.
Figure 6
Figure 6
Breast tumors with basal-like gene expression and basal epithelial cells differentially express hypoxia-related genes. A significant positive correlation between basal-like and hypoxia-related gene expression was observed in breast tumors in the (A) primary (n = 1,143, P <0.0001) and (D) validation (n = 547, P <0.0001) datasets. A significant positive relationship was observed between HIF-1α gene expression and hypoxia-related gene expression in the (B) primary (n = 1,143, P <0.0001) and (E) validation (n = 547, P <0.0001) datasets. A significant positive relationship was observed between HIF-1α gene expression and basal-like gene expression in the (C) primary (n = 1,143, P <0.0001) and (F) validation (n = 547, P <0.0001) datasets. (G) Normal basal epithelial cells express higher mRNA levels of HIF-1α (P <0.0001) and EPAS1 (HIF-2α) (P <0.0001) as compared to normal breast luminal cells. (H) Normal basal epithelial cells demonstrate higher mRNA levels of three hypoxia-induced genes (CA9, Glut1, and VEGFA) under normal and hypoxic conditions as compared to normal luminal epithelia.
Figure 7
Figure 7
HIF-1α silencing inhibits the exaggerated hypoxia response in basal and subgroup 7 cancer cell lines. (A) Basal breast cancer cell line demonstrate higher HIF-1α mRNA levels when compared to luminal breast cancer cell lines (B) Basal breast cancer cell line demonstrate higher VEGF mRNA levels when compared to luminal breast cancer cell lines. (C, D) The silencing of HIF-1α but not EPAS1 (HIF-2α mRNA by siRNA inhibits hypoxia-induced gene expression (VEGF) levels in basal breast cancer cell lines (C) and HER2-basal subtypes cell lines (D) under both normal and hypoxic conditions as compared to their respective luminal-type breast cancer cell lines.

Similar articles

Cited by

References

    1. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature. 2000;406:747–752. doi: 10.1038/35021093. - DOI - PubMed
    1. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, Porter D, Hu M, Chin L, Richardson A, Schnitt S, Sellers WR, Polyak K. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell. 2004;6:17–32. doi: 10.1016/j.ccr.2004.06.010. - DOI - PubMed
    1. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, Lapuk A, Neve RM, Qian Z, Ryder T, Chen F, Feiler H, Tokuyasu T, Kingsley C, Dairkee S, Meng Z, Chew K, Pinkel D, Jain A, Ljung BM, Esserman L, Albertson DG, Waldman FM, Gray JW. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell. 2006;10:529–541. doi: 10.1016/j.ccr.2006.10.009. - DOI - PubMed
    1. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006;10:515–527. doi: 10.1016/j.ccr.2006.10.008. - DOI - PMC - PubMed
    1. Visvader JE. Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes Dev. 2009;23:2563–2577. doi: 10.1101/gad.1849509. - DOI - PMC - PubMed

Publication types

MeSH terms